ESC 365 - To compare efficacy and safety of direct oral anticoagulants in patients with concurrent atrial fibrillation and bioprosthetic heart valve repair or replacement: a systematic review and meta-analysis

ESC Professional Premium Access

To compare efficacy and safety of direct oral anticoagulants in patients with concurrent atrial fibrillation and bioprosthetic heart valve repair or replacement: a systematic review and meta-analysis

Session: Thrombosis and anticoagulation in valvular heart disease

Topic: Prosthetic Heart Valves

Speaker: Doctor A. Kaur (New York City, US)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Doctor Arpanjeet Kaur

Icahn School of Medicine at Mount Sinai Morningside West, New York City (United States of America)

0 follower

4 more presentations in this session

Oral anticoagulant treatment in patients with atrial fibrillation early after valvular intervention: a nationwide cohort study

Speaker: Associate Professor C. Christersson (Uppsala, SE)

Comparing direct oral anticoagulants versus vitamin k antagonist in patients with atrial fibrillation after transcatheter aortic valve replacement: an updated meta-analysis

Speaker: Doctor A. Kaur (New York City, US)

Risk factors and clinical effects of late leaflet thrombosis after transcatheter aortic valve replacement

Speaker: Doctor M. Bak (Seoul, KR)

Hypoattenuated leaflet thickening is associated with silent brain injury

Speaker: Doctor A. Nagy (Budapest, HU)

Access the full session

Thrombosis and anticoagulation in valvular heart disease

Speakers: Doctor A. Kaur, Associate Professor C. Christersson, Doctor A. Kaur, Doctor M. Bak, Doctor A. Nagy

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources